Termination Of Ventricular Tachycardia Research Articles

Differentiation of high frequency near field versus far-field potentials in low voltage zones during sinus rhythm improves discrimination of local sites of termination during ventricular tachycardia

Abstract Background Ventricular tachycardia (VT) with structural heart disease (SHD) is often bad tolerated or presents with several inducible morphologies, this support mapping the arrhythmic substrate during sinus rhythm (SR). Poor discrimination between near-field (NF) and far-field (FF) electrogram (EGM) components in low voltage (LV) areas is the main limitation. The peak frequency (PF) associated with bipolar EGMs may distinguish NF from FF EGMs (Panel D). Objective To evaluate if PF combined with voltage mapping during SR enhances discrimination of the region of VT termination by radiofrequency application (RFa). Methods Bipolar activation and voltage maps were generated with a 16-pole grid catheter (HD Grid) during SR (Panel B). PF maps were retrospectively computed (Panel C). The maps were only analyzed if acute termination was achieved by focal RFa within a boundary diameter <1.5cm (Panel A). The mapped surface area (SA) was sub-regioned in termination (T-ZONE) and non-termination (NT-ZONE) zones. The T-ZONE surface was centered about the termination site and was allowed to extend to a rectangular kernel >0.5cm and <1.5cm across perpendicular axes, with the NT-ZONE encompassing the remainder mapped SA. Sensitivity (SE) and specificity (SP) of discrimination of the T-ZONE vs. NT-ZONE were measured according to the %SA covered at different LV thresholds (0.1-1.0mV in increments of 0.1mV - Panel F). LV high PF (LVHF) areas at different PF cutoffs from 150Hz (LVHF150) to 300Hz (LVHF300) were also assessed. Results 15 patients with SHD and sustained monomorphic VT were enrolled. 4 had 5 VT’s terminated by 1.4±0.9 focal RF lesions (60-74 y/o, 3 ischemic). All termination sites were located in a LVHF region mapped during SR (Panels B,C,E). The T-ZONE occupied 0.41±0.33cm /92.75±13.31cm global SA and consisted of 15±10 EGM points/1432±337 global points. T-ZONE voltage during SR (0.50±0.32mV) was significantly lower vs. global voltage (2.01±0.69mV, P<0.001), while T-ZONE PF was higher (324±51Hz) vs. global (270±37Hz, P<0.001). ROC discrimination of the T-ZONE yielded AUC’s of 0.79-LV alone, 0.87- LVHF150, 0.91-LVHF200 (Delta +12.2% vs LV alone, Panel F), 0.85-LVHF250 and 0.77-LVHF300. At a 0.7mV cutoff, LVHF200 yielded a balanced SE/SP of 0.89/0.87 vs. LV alone (0.90/0.63). Conclusion Assessment of regions with LVHF during SR improves SP for discrimination of sites of VT termination compared to LV alone.TV near field

Cardiac Memory T Waves After Termination of Fascicular Ventricular Tachycardia in the Emergency Room

Left posterior fascicular tachycardia (LPFVT) is a common type of idiopathic ventricular tachycardia that might be misdiagnosed as supraventricular tachycardia. Memory T wave is an inverted T wave that is seen after altered depolarization states such as pacemaker rhythm, ablated accessory pathways, ventricular tachycardia, or intermittent bundle branch blocks. Herein, we presented a young male patient who was admitted to the emergency room with FVT. After termination of tachycardia negative T waves (memory T wave) were seen. Memory T waves might be seen after the termination of FVT and must be differentiated from other causes of inverted T waves such as ischemia.

Comparison of novel intrinsic versus conventional antitachycardia pacing for ventricular tachycardia among implantable cardioverter-defibrillator recipients.

Intrinsic antitachycardia pacing (iATP) is a novel automated antitachycardia pacing (ATP) that provides individual treatment to terminate ventricular tachycardia (VT). However, the clinical efficacy of iATP in comparison with conventional ATP is unknown. We aim to compare the termination rate of VT between iATP and conventional ATP in patients with implantable cardioverter-defibrillators using a unique setting of different sequential orders of both ATP algorisms. Patients with the iATP algorithm were assigned to iATP-first and conventional ATP-first groups sequentially. In the iATP-first group, a maximum of seven iATP sequences were delivered, followed by conventional burst and ramp pacing. In contrast, in the conventional ATP-first group, two bursts and ramp pacing were initially programmed, followed by iATP sequences. We compared the success rates of VT termination in the first and secondary programmed ATP zones between the two groups. Fifty-eight and 56 patients were enrolled in the iATP-first and conventional ATP-first groups, and 67 and 44 VTs were analyzed in each group, respectively. At the first single ATP therapy, success rates were 64% and 70% in the iATP and conventional groups, respectively. At the end of the first iATP treatment zone, the success rate increased from 64% to 85%. Moreover, secondary iATP therapy following the failure of conventional ATPs increased the success rate from 80% to 93%. There was a significant benefit of alternative iATP for VT termination compared to secondary conventional ATP (100% vs. 33%, p = .028). iATP may be beneficial as a secondary therapy after failure of conventional ATP to terminate VT.

Real-world performance of a fully automatic antitachycardia pacing algorithm

Abstract Background Antitachycardia pacing (ATP) found in most implantable cardioverter defibrillators (ICDs) is an important therapy for painless termination of ventricular tachycardias (VT). In ICDs programmed to guideline-recommended detection and therapy settings typical ATP success rates are 50-70%.[1-3] The first closed-loop, automated ATP (AATP) algorithm, introduced in 2021, applies an S1 train derived from the detected VT, followed by an S2 derived initially from a refractory period estimator and then adjusted using analysis of the post-pacing interval if ATP fails. The termination efficacy of AATP in the real-world population is unknown. Purpose To assess the effectiveness AATP in a large real-world population. Methods A database of de-identified ICD transmissions from subjects in the United States, Australia, Canada, and New Zealand was queried for AATP treated episodes. ICDs were randomly sampled, biased toward ICDs with multiple treated VT episodes. For rhythms classified as monomorphic ventricular tachycardia, each AATP pulse train was reviewed for: rhythm at delivery, effect of ATP, and any non-capturing pulses. Acceleration was defined as a post-ATP decrease in MVT cycle length (VTCL) of at least 10% and at least 30ms. Acceleration to polymorphic VT or ventricular fibrillation (PVT/VF) was assessed. Rates of termination and acceleration were calculated for all MVT and dichotomized using a 320ms VTCL cutoff. The method of generalized estimating equations (GEE) was used to correct event rates for multiple episodes from a single patient. Results There were 2281 episodes of MVT in 340 patients; 63% of patients had 2 or more episodes. There were 724 episodes with initial VTCL <320ms and 1557 episodes with VTCL ≥320ms. The rate of termination of MVT by AATP was 78% for all VTCL [95% CI: 74%-81%]. In 300 patients (88%) AATP terminated at least one MVT. For MVT with VTCL ≥320ms the termination rate was 80% [95% CI: 75%-83%] and for VTCL <320ms the termination rate was 75% [95% CI: 69%-80%]. The rate of acceleration was 3.6% [95% CI: 2.7%-4.9%], with a 0.8% rate of acceleration to PVT/VF [95% CI: 0.4%-1.8%]. Acceleration led to shock therapy in 63% of accelerated episodes. All MVT accelerated to PVT/VF either spontaneously terminated (4/14) or were successfully converted by a single shock therapy (10/14). All accelerations that remained MVT were successfully treated by the device with either subsequent ATP (35%) or shock therapy (61%), or spontaneously terminated (4%). Conclusion In this large, real-world cohort analysis, automated ATP’s termination rate exceeded the typical success rate of burst ATP, particularly for MVT <320ms. Acceleration to PVT/VF was low and effective first-shock defibrillation was consistent. Subsequent ATP for accelerated MVT had incremental benefit, leading to successful termination one-third of the time. Additional data are currently being prospectively collected in a separate post-approval study.

Machine learning-derived cycle length variability metrics predict spontaneously terminating ventricular tachycardia in implantable cardioverter defibrillator recipients.

Implantable cardioverter defibrillator (ICD) therapies have been associated with increased mortality and should be minimized when safe to do so. We hypothesized that machine learning-derived ventricular tachycardia (VT) cycle length (CL) variability metrics could be used to discriminate between sustained and spontaneously terminating VT. In this single-centre retrospective study, we analysed data from 69 VT episodes stored on ICDs from 27 patients (36 spontaneously terminating VT, 33 sustained VT). Several VT CL parameters including heart rate variability metrics were calculated. Additionally, a first order auto-regression model was fitted using the first 10 CLs. Using features derived from the first 10 CLs, a random forest classifier was used to predict VT termination. Sustained VT episodes had more stable CLs. Using data from the first 10 CLs only, there was greater CL variability in the spontaneously terminating episodes (mean of standard deviation of first 10 CLs: 20.1 ± 8.9 vs. 11.5 ± 7.8 ms, P < 0.0001). The auto-regression coefficient was significantly greater in spontaneously terminating episodes (mean auto-regression coefficient 0.39 ± 0.32 vs. 0.14 ± 0.39, P < 0.005). A random forest classifier with six features yielded an accuracy of 0.77 (95% confidence interval 0.67 to 0.87) for prediction of VT termination. Ventricular tachycardia CL variability and instability are associated with spontaneously terminating VT and can be used to predict spontaneous VT termination. Given the harmful effects of unnecessary ICD shocks, this machine learning model could be incorporated into ICD algorithms to defer therapies for episodes of VT that are likely to self-terminate.

Utility of Very High-Output Pacing to Identify VT Circuits in Patients Manifesting Traditionally Inexcitable Scar

BackgroundEntrainment and pace mapping are used to identify critical components (CCs) of ventricular tachycardia (VT) circuits. In patients with dense myocardial scarring, VT circuits may elude capture at standard high pacing outputs (up to 10 mA at a 2-millisecond pulse width). ObjectivesThe purpose of this study was to assess the utility of very high–output pacing (V-HOP, 50 mA at 2 milliseconds) for identifying CCs of VT circuits after standard high pacing output failed to elicit capture in densely scarred myocardial tissue. MethodsOur standard VT ablation approach included electroanatomic mapping for substrate characterization and entrainment and/or pace mapping to identify CCs of VT circuits. Patients that required V-HOP to capture sites of interest comprised the study cohort. Ablation endpoints were VT termination and noninducibility. ResultsTwenty-five patients (71 ± 10 years of age, all males) undergoing 26 VT ablations met the inclusion criteria. The mean left ventricular ejection fraction was 30% ± 14%, and 85% had ischemic cardiomyopathy. V-HOP was used to successfully entrain VT in 17 patients, yielding central isthmus sites in 10 and entrance/exit sites in 4. VT terminated with radiofrequency ablation at these sites in 15 patients. In 9 patients, V-HOP identified scar locations with a delayed exit. Acute procedural success was achieved in 24 patients without any adverse events. Over a follow-up period of 16 ± 21 months, 2 patients experienced VT recurrence requiring repeat ablation during which the same location was targeted successfully in 1 patient. ConclusionsIn VT patients with a dense scar that is traditionally inexcitable, V-HOP can identify CCs of the re-entrant circuit and guide successful ablation.

Arrhythmogenicity of anti-tachycardia pacing in patients with implantable cardioverter defibrillator

BackgroundAnti-tachycardia pacing therapy (ATP) has shown comparable efficacy to shock therapy in ventricular tachycardia (VT) termination with better quality of life. However, some ATPs may lead to VT acceleration or degeneration to ventricular fibrillation (VF), which will result in more ICD shocks. The aim of this study was to investigate the predictors of VT acceleration by ATP therapy in a real-life patient cohort.ResultsWe retrospectively reviewed 448 monomorphic VT episodes that required ATP therapy in 60 patients with structural heart diseases implanted with ICD or CRTD. The clinical data of the patients and the episodes’ details were evaluated. We found that patients with a higher ejection fraction (EF) were more likely to be cardioverted by ATP therapy (P: 0.024). VT acceleration was more frequent in patients with lower EF (mean 31.24 ± 4.08) compared with the non-accelerated patients with higher EF (mean 37.00 ± 9.4, P: 0.016). The percentage of accelerated episodes was 8.5%. VT episodes with a mean cycle length (CL) < 310 ms are more likely to accelerate (sensitivity 76.3%, specificity 67.7%, PPV value 45%, NPV 86%, and AUC 0.790). There was a statistically significant difference in the accelerated VT episodes as compared to non-accelerated episodes regarding the number of ATP bursts (mean 3.66 ± 2.22 vs. 1.76 ± 1.35, P: < 0.001), ramp (23.7% vs. 4.2%, P: < 0.001), scanning (55.3% vs. 31.3%, P: 0.003) and burst adaptive cycle length (mean 83.55 ± 2.92 vs. 84.64 ± 2.61, P: 0.016). In a multivariate analysis, the VT CL, number of ATP bursts and ramp pacing predicted VT acceleration by ATP therapy.ConclusionsVentricular tachycardia in patients with low LV EF and fast VTs with a CL less than 310 ms were more likely to accelerate with ATP therapy. The number of ATP bursts and the use of ramp had a significant effect on VT acceleration. To avoid VT acceleration by ATP therapy, ramp pacing better be avoided, especially in fast VTs, and lesser number of bursts should be delivered.

Peak frequency mapping to differentiate near-field from far-field electrograms for ventricular tachycardia ablation: initial results

Abstract Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Abbott Laboratories Background Ablation of ventricular tachycardia (VT) in patients with structural heart disease is challenging. Localization of the critical isthmus of conduction may be difficult because is commonly located within low voltage (LV) areas where far-field (FF) and near-field (NF) electrograms (EGMs) may be present and merged. The peak frequency (PF) associated with bipolar EGMs is a novel parameter which may serve to distinguish NF from FF EGM components. The potential value of PF to identify the critical isthmus of conduction in this setting has never been evaluated. Purpose To compare the ability of LV vs. LVHF to discriminate the VT termination region Methods Bipolar voltage and activation maps were generated with a 16-pole grid catheter (Advisor HD Grid) during VT. Peak frequency maps were retrospectively computed. VTs were included if acute termination could be achieved through application of a focal RF lesions set restricted to a boundary &amp;lt;1.5cm diameter. The ventricular LV mapped surface was sub-regioned into the termination (T-ZONE) and non-termination (NT-ZONE) zones. The T-ZONE surface was centered about the site of termination and was allowed to extend to a rectangular kernel &amp;gt;0.5cm and &amp;lt;1.5cm across perpendicular axes, with the NT-ZONE encompassing the remainder of the mapped surface area (SA). Sensitivity (SE) and specificity (SP) of discrimination of the T-ZONE vs. NT-ZONE was measured according to the %T-ZONE vs. %NT-ZONE SA occupied at LV thresholds ranging from 0.1-1.0mV in increments of 0.1mV (Panel E). In addition to LV, LVHF at peak frequency cutoffs of 200Hz (LVHF200), 250Hz (LVHF250), 300Hz (LVHF300) and 400Hz (LVHF400) were also assessed for T-ZONE discrimination. Results 8 patients with sustained monomorphic VT and structural heart disease (ischemic and non-ischemic) were enrolled. All of them had VT terminated with limited ablation by focal ablation at a discrete region. All areas of VT termination were located in a LV and high PF zone (figure 1). The best area under the curve to identify them was using the 250 Hz cuttoff (AUC 0.91) which was also better that using omnipolar optimized voltage alone (AUC 0.84) (Figure 2). Conclusion PF mapping apparently identifies slow conduction isthmus and provides complementary information to bipolar voltage mapping which can be displayed with emphasis on the electranatomical map.

Sex differences in catheter ablation for ventricular tachycardia in structural heart disease: a single center 10-years experience

Abstract Funding Acknowledgements Type of funding sources: None. Background Women are underrepresented in studies concerning ventricular tachycardia (VT) catheter ablation (CA). Different etiologies and type of structural heart diseases (SHD) are well established in women; nonetheless conflicting results about efficacy and safety of CA in women have been reported. Purpose To evaluate acute and long-term outcome of VT CA in SHD in women compared to men in a high-volume tertiary Center. Methods All consecutive procedures were included from January 2010 to December 2021. Clinical characteristics, VT etiologies and procedure data of female patients were compared to male population. Catheter ablation was performed according to standard protocol in our center. In mappable VTs, the reentry circuit was characterized, and ablation aimed at VT interruption during radiofrequency (RF); otherwise, a substrate modification approach aiming at late potentials abolition or ablation at sites of slow conduction during sinus rhythm was performed. Following ablation, prevention of any VT inducibility and substrate modification was considered ablation endpoint. Acute results, complications, and VT recurrences during follow up were analyzed comparing the two groups. Results Among 1608 overall VT CA procedures, 141 procedures were performed in 117 women. Female were younger, with less comorbidities, less ischemic VT etiology and higher left ventricular ejection fraction (LVEF) as compared to men (Table 1). They were also less likely ICD carriers. No significant differences were found with regards to: epicardial approach (39.7% vs 35.3%, p=0.68); VT inducibility at baseline (57.4% vs 67.6%, p=0.14), VT termination during RF (87.6% vs 77.6%, p=0.51), and prevention of any VT inducibility at the programmed electrical stimulation (PES) after ablation (79.5% vs 78.1%, p=0.7). Major complications occurred in 4.9% of females as compared to 4.3% of male patients. At median follow-up of 25 months, VT recurrences occurred in 24.7% of female population and 27.5% of male group (p=0.42). Cumulative VT-free survival was comparable in both groups (Figure 2). Conclusions Women with SHD have favorable acute and long-term outcome of VT ablation, despite a high prevalence of non-ischemic etiologies. VT recurrence rate and procedure safety is comparable to male patients, suggesting that catheter ablation can be offered as an effective treatment to women with refractory ventricular arrhythmias.

Microelectrode voltage mapping for substrate assessment in catheter ablation of ventricular tachycardia: a dual-center experience

Abstract Funding Acknowledgements Type of funding sources: None. Background The assessment of the ventricular myocardial substrate critically depends on the size of mapping electrodes, their orientation with respect to wavefront propagation, and interelectrode distance. Objective we conducted a dual-center study to evaluate the impact of microelectrode mapping in patients undergoing catheter ablation (CA) of ventricular tachycardia (VT). Methods We included 21 consecutive patients (median age, 68 [12], 95% male) with structural heart disease undergoing CA for electrical storm (n=14) or recurrent VT (n=7) using the QDOT Micro catheter and a multipolar catheter (PentaRay, n=9). The associations of peak-to-peak maximum standard bipolar (BVc) and minibipolar (PentaRay, BVp) with microbipolar (BVμMax) voltages were respectively tested in sinus rhythm with mixed effect models. Furthermore, we compared the features of standard bipolar (BE) and microbipolar (μBE) electrograms in sinus rhythm at sites of termination with radiofrequency energy. Results BVμMax was moderately associated with both BVc (β=0.85, p&amp;lt;0.01) and BVp (β=0.56, p&amp;lt;0.01). BVμMax was 0.98 (95% CI, 0.93-1.04, p&amp;lt;0.01) mV larger than corresponding BVc, and 0.27 (95% CI, 0.16-0.37, p&amp;lt;0.01) mV larger than matching BVp in sinus rhythm, with higher percentage differences in low voltage regions, leading to smaller endocardial dense scar (2.3 [2.7] vs. 12.1 [17] cm2, p&amp;lt;0.01) and border zone (3.2 [7.4] vs. 4.8 [20.1] cm2, p=0.03) regions in microbipolar maps compared to standard bipolar maps. At sites of VT termination (n=14), μBE were of higher amplitude (0.9 [0.8] mV versus 0.4 [0.2] mV, p&amp;lt;0.01), longer duration (117 [66] ms versus 74 [38] ms, p&amp;lt;0.01), and with greater number of peaks (4 [2] versus 2 [1], p&amp;lt;0.01) in sinus rhythm compared to BE. Conclusions Microelectrode mapping is more sensitive than standard bipolar mapping in the identification of viable myocytes in SR, and may facilitate recognition of targets for catheter ablation.

PO-04-228 DIFFERENTIATION OF HIGH FREQUENCY NEAR FIELD VS. FAR-FIELD POTENTIALS IN LOW VOLTAGE ZONES DURING SINUS RHYTHM IMPROVES DISCRIMINATION OF LOCAL SITES OF TERMINATION DURING VT

Ventricular tachycardia (VT) in patients with structural heart disease (SHD) is often poorly tolerated or presents with several inducible morphologies. These factors support mapping the arrhythmic substrate during sinus rhythm (SR). However, poor discrimination between near-field (NF) and far-field (FF) electrogram (EGM) components in low voltage (LV) areas is the main limitation. The peak frequency (PF) associated with bipolar EGMs may distinguish NF from FF EGMs (Panel D). To evaluate if PF combined with voltage mapping during SR enhances discrimination of the region of VT termination by radiofrequency application (RFa). Bipolar activation and voltage maps were generated with a 16-pole grid catheter (HD Grid) during SR (Panel B). PF maps were retrospectively computed (Panel C). The maps were only analysed if acute termination was achieved by focal RFa within a boundary diameter<1.5cm (panel A). The mapped surface area (SA) was sub-regioned into the termination (T-ZONE) and non-termination (NT-ZONE) zones. The T-ZONE surface was centered about the termination site and was allowed to extend to a rectangular kernel >0.5cm and <1.5cm across perpendicular axes, with the NT-ZONE encompassing the remainder mapped SA. Sensitivity (SE) and specificity (SP) of discrimination of the T-ZONE vs. NT-ZONE were measured according to the %SA covered at different LV thresholds (0.1-1.0mV in increments of 0.1mV - Panel F). LV high PF (LVHF) areas at different PF cutoffs from 150Hz (LVHF150) to 300Hz (LVHF300) were also assessed. 15 patients with SHD and sustained monomorphic VT were enrolled. Four (60-74 years, all male, 3 ischemic) of them had 5 VT’s terminated by 1.4±0.9 focal RF lesions. All termination sites were located in a LVHF region mapped during SR (Panels B,C,E). The T-ZONE occupied 0.41±0.33cm2/92.75±13.31cm2 global SA, and consisted of 15±10 EGM points/1432±337 global points. T-ZONE voltage during SR (0.50±0.32mV) was significantly lower vs. global voltage (2.01±0.69mV, P<0.001), while T-ZONE PF was higher (324±51Hz) vs. global (270±37Hz, P<0.001). ROC discrimination of the T-ZONE yielded AUC’s of 0.79-LV alone, 0.87-LVHF150, 0.91-LVHF200 (Delta +12.2% vs LV alone, Panel F), 0.85-LVHF250 and 0.77-LVHF300. At a 0.7mV cutoff, LVHF200 yielded a balanced SE/SP of 0.89/0.87 vs. LV alone (0.90/0.63). Assessment of regions with LV and high PF during SR improves specificity for discrimination of sites of VT termination compared to LV alone.

Microelectrode voltage mapping for substrate assessment in catheter ablation of ventricular tachycardia: A dual-center experience.

The assessment of the ventricular myocardial substrate critically depends on the size of mapping electrodes, their orientation with respect to wavefront propagation, and interelectrode distance. We conducted a dual-center study to evaluate the impact of microelectrode mapping in patients undergoing catheter ablation (CA) of ventricular tachycardia (VT). We included 21 consecutive patients (median age, 68 [12], 95% male) with structural heart disease undergoing CA for electrical storm (n = 14) or recurrent VT (n = 7) using the QDOT Micro catheter and a multipolar catheter (PentaRay, n = 9). The associations of peak-to-peak maximum standard bipolar (BVc ) and minibipolar (PentaRay, BVp ) with microbipolar (BVμMax ) voltages were respectively tested in sinus rhythm with mixed effect models. Furthermore, we compared the features of standard bipolar (BE) and microbipolar (μBE) electrograms in sinus rhythm at sites of termination with radiofrequency energy. BVμMax was moderately associated with both BVc (β = .85, p < .01) and BVp (β = .56, p < .01). BVμMax was 0.98 (95% CI: 0.93-1.04, p < .01) mV larger than corresponding BVc , and 0.27 (95% CI: 0.16-0.37, p < .01) mV larger than matching BVp in sinus rhythm, with higher percentage differences in low voltage regions, leading to smaller endocardial dense scar (2.3 [2.7] vs. 12.1 [17] cm2 , p < .01) and border zone (3.2 [7.4] vs. 4.8 [20.1] cm2 , p = .03) regions in microbipolar maps compared to standard bipolar maps. Late potentials areas were nonsignificantly greater in microelectrode maps, compared to standard electrode maps. At sites of VT termination (n = 14), μBE were of higher amplitude (0.9 [0.8] vs. 0.4 [0.2] mV, p < .01), longer duration (117 [66] vs. 74 [38] ms, p < .01), and with greater number of peaks (4 [2] vs. 2 [1], p < .01) in sinus rhythm compared to BE. microelectrode mapping is more sensitive than standard bipolar mapping in the identification of viable myocytes in SR, and may facilitate recognition of targets for CA.

Fascicular ventricular tachycardia arising from the left side His and its adjacent region: a subset of upper septal idiopathic left ventricular tachycardia.

Fascicular ventricle tachycardia (FVT) arising from the proximal aspect of left His-Purkinje system (HPS) has not been specially addressed. Current study was to investigate its clinical, electrocardiographic, and electrophysiological characteristics. Eighteen patients who were identified as this rare FVT were consecutively enrolled, and their scalar electrocardiogram and electrophysiological data were collected and analysed. The ventricular tachycardia (VT) morphology was similar to sinus rhythm (SR) in eight patients, left bundle branch block type in one patient, right bundle branch block type in seven patients, and both narrow and wide QRS type in two patients. During VT, right-sided His potential preceded the QRS with His-ventricle (H-V) interval of 36.3 ± 12.4 ms, which was shorter than that during SR (-51.4 ± 8.6 ms) (P = 0.002). The earliest Purkinje potentials (PPs) were recorded within 7 ± 3 mm of left-side His and preceded the QRS by 49.1 ± 14.0 ms. Mapping along the left anterior fascicle and left posterior fascicle revealed an antegrade activation sequence in all with no P1 potentials recorded. In the two patients with two VT morphologies, the earliest PP was documented at the same site, and the activation sequence of HPS remained antegrade. Ablation at the earliest PP successfully eliminated the tachycardia, except one patient who developed complete atrial-ventricular block and two patients who abandoned ablations. After at least 12 months follow-up, 15 patients were free from any recurrences. Fascicular ventricle tachycardia arising from the proximal aspect of left HPS was featured by recording slightly shorter H-V interval and absence of P1 potentials. Termination of VT requires ablation at the left-sided His or its adjacent region.

Optimization of anti-tachycardia pacing efficacy through scar-specific delivery and minimization of re-initiation: a virtual study on a cohort of infarcted porcine hearts.

Anti-tachycardia pacing (ATP) is a reliable electrotherapy to painlessly terminate ventricular tachycardia (VT). However, ATP is often ineffective, particularly for fast VTs. The efficacy may be enhanced by optimized delivery closer to the re-entrant circuit driving the VT. This study aims to compare ATP efficacy for different delivery locations with respect to the re-entrant circuit, and further optimize ATP by minimizing failure through re-initiation. Seventy-three sustained VTs were induced in a cohort of seven infarcted porcine ventricular computational models, largely dominated by a single re-entrant pathway. The efficacy of burst ATP delivered from three locations proximal to the re-entrant circuit (septum) and three distal locations (lateral/posterior left ventricle) was compared. Re-initiation episodes were used to develop an algorithm utilizing correlations between successive sensed electrogram morphologies to automatically truncate ATP pulse delivery. Anti-tachycardia pacing was more efficacious at terminating slow compared with fast VTs (65 vs. 46%, P = 0.000039). A separate analysis of slow VTs showed that the efficacy was significantly higher when delivered from distal compared with proximal locations (distal 72%, proximal 59%), being reversed for fast VTs (distal 41%, proximal 51%). Application of our early termination detection algorithm (ETDA) accurately detected VT termination in 79% of re-initiated cases, improving the overall efficacy for proximal delivery with delivery inside the critical isthmus (CI) itself being overall most effective. Anti-tachycardia pacing delivery proximal to the re-entrant circuit is more effective at terminating fast VTs, but less so slow VTs, due to frequent re-initiation. Attenuating re-initiation, through ETDA, increases the efficacy of delivery within the CI for all VTs.

Characterization of the right ventricular substrate participating in postinfarction ventricular tachycardia.

The right ventricle (RV) is uncommonly implicated in postinfarction ventricular tachycardia (VT). The prevalence and features of the RV substrate participating in postinfarction VT are undefined. The purpose of this study was to characterize critical right ventricular substrate (CRVS) involvement in patients with postinfarction VT. We retrospectively reviewed 1279 patients with postinfarction VT undergoing catheter ablation at our center from January 2000 through May 2020. Cases with CRVS defined by conclusive demonstration of participation in VT with activation, entrainment, and/or pacemapping during sinus rhythm were identified. CRVS was identified in 27 of 1279 patients (2.1%): age 65± 13 years, 96% male, median left ventricular (LV) ejection fraction 25%, and 93% with left bundle branch block (LBBB) morphology VT. CRVS was identified by RV activation and/or entrainment mapping (n = 19) or by the presence of low-voltage abnormal electrograms with excellent pacemap for the targeted VT and noninducibility after ablation (n = 8). VT termination during RV ablation occurred in 15 patients. After median follow-up of 20 months (interquartile range 9-53 months) and median of 2 procedures (interquartile range 1-3), 22 of 27 patients (80%) had no VT recurrence and 11 (41%) died. The RV contains critical substrate elements of postinfarction VT in at least 2.1% of cases. RV mapping should be considered in cases in which LV mapping fails to demonstrate adequate targets, particularly in patients with LBBB morphology VT.

Ultra-low power deep sustained optogenetic excitation of human ventricular cardiomyocytes with red-shifted opsins: a computational study.

The main challenge in cardiac optogenetics is to have low-power, high-fidelity deep excitation of cells with minimal invasiveness and heating. We present a detailed computational study of optogenetic excitation of human ventricular cardiomyocytes (HVCMs) with new ChRmine, bReaChES and CsChrimson red-shifted opsins to overcome the challenge. Action potentials (APs) in ChRmine-expressing HVCMs can be triggered at 6µWmm-2 (10ms pulse) and 0.7µWmm-2 (100ms pulse) at 585nm, which is two orders of magnitude lower than ChR2(H134R). This enables safe sustained excitation of deeply situated cardiac cells with ChRmine (7.46mm) and with bReaChES (6.21mm) with the light source at the pericardium surface. Deeper excitation up to 10.2mm can be achieved with ChRmine by illuminating at 650nm. Photostimulation conditions for minimum charge transfer during APs have been determined, which is important for tissue health under sustained excitation. The AP duration for all the opsins is constant up to 100ms pulse width but increases thereafter. Interestingly, the AP frequency increases with irradiance under continuous illumination, but APs are suppressed at higher irradiances. The optimal range of irradiance for each opsin to excite HVCMs has been determined. Under optimal photostimulation conditions, each opsin can precisely excite APs up to 2.5Hz, while latency and power of light pulse for each AP in a sequence remain most stable and an order of magnitude lower, respectively, in ChRmine-expressing HVCMs. The study highlights the importance of ChRmine and bReaChES for resynchronization, termination of ventricular tachycardia and designing optogenetic cardiac pacemakers with enhanced battery life. KEY POINTS: This work is the formulation of accurate theoretical models of optogenetic control of human ventricular cardiomyocytes (HVCMs) expressed with newly discovered opsins (ChRmine, bReaChES and CsChrimson). Under continuous illumination, action potentials in each opsin-expressing HVCMs can only be evoked in a certain range of irradiances. Action potentials in ChRmine-expressing HVCMs can be triggered at ultra-low power (6µWmm-2 at 10ms pulse or 0.7µWmm-2 at 100ms pulse at 585nm), which is two to three orders of magnitude lower than reported results. Ongoing action potentials in ChRmine-expressing HVCMs can be suppressed by continuous illumination of 585nm light at 2µWmm-2 . ChRmine enables sustained excitation due to its faster recovery from the desensitized state. Optogenetic excitation of deeply situated cardiac cells is possible up to ∼7.46and 10.2mm with ChRmine on illuminating the outer surface of pericardium at safe irradiance at 585nm and 650nm, respectively. The study opens up prospects for designing energy-efficient light-induced pacemakers, resynchronization and termination of ventricular tachycardia.

Stereotactic body radioablation therapy as an immediate and early term antiarrhythmic palliative therapeutic choice in patients with refractory ventricular tachycardia.

BackgroundStereotactic body radioablation therapy (SBRT) has recently been introduced with the ability to provide ablative energy noninvasively to arrhythmogenic substrate while reducing damage to normal cardiac tissue nearby and minimizing patients’ procedural risk. There is still debate regarding whether SBRT has a predominant effect in the early or late period after the procedure. We sought to assess the time course of SBRT’s efficacy as well as the value of using a blanking period following a SBRT session.MethodsEight patients (mean age 58 ± 14 years) underwent eight SBRT sessions for refractory ventricular tachycardia (VT). SBRT was given using a linear accelerator device with a total dose of 25 Gy to the targeted area.ResultsDuring a median follow-up of 8 months, all patients demonstrated VT recurrences; however, implantable cardioverter-defibrillator (ICD) and anti-tachycardia pacing therapies were significantly reduced with SBRT (8.46 to 0.83/per month, p = 0.047; 18.50 to 3.29/per month, p = 0.036, respectively). While analyzing the temporal SBRT outcomes, the 2 weeks to 3 months period demonstrated the most favorable outcomes. After 6 months, one patient was ICD therapy-free and the remaining patients demonstrated VT episodes.ConclusionsOur findings showed that the SBRT was associated with a marked reduction in the burden of VT and ICD interventions especially during first 3 months. Although SBRT does not seem to succeed complete termination of VT in long-term period, our findings support the strategy that SBRT can be utilized for immediate antiarrhythmic palliation in critically ill patients with otherwise untreatable refractory VT and electrical storm.

Distinct spectral dynamics of implanted cardiac defibrillator signals in spontaneous termination of polymorphic ventricular tachycardia and fibrillation in patients with electrical and structural diseases.

To determine the spectral dynamics of early spontaneous polymorphic ventricular tachycardia and ventricular fibrillation (PVT/VF) in humans. Fifty-eight self-terminated and 173 shock-terminated episodes of spontaneously initiated PVT/VF recorded by Medtronic implanted cardiac defibrillators (ICDs) in 87 patients with various cardiac pathologies were analyzed by short fast Fourier transform of shifting segments to determine the dynamics of dominant frequency (DF) and regularity index (RI). The progression in the intensity of DF and RI accumulations further quantified the time course of spectral characteristics of the episodes. Episodes of self-terminated PVT/VF lasted 8.6 s [95% confidence interval (CI): 8.1-9.1] and shock-terminated lasted 13.9 s (13.6-14.3) (P < 0.001). Recordings from patients with primarily electrical pathologies displayed higher DF and RI values than those from patients with primarily structural pathologies (P < 0.05) independently of ventricular function or antiarrhythmic drug therapy. Regardless of the underlying pathology, the average DF and RI intensities were lower in self-terminated than shock-terminated episodes [DF: 3.67 (4.04-4.58) vs. 4.32 (3.46-3.93) Hz, P < 0.001; RI: 0.53 (0.48-0.56) vs. 0.63 (0.60-0.65), P < 0.001]. In a multivariate analysis controlled by the type of pathology and clinical variables, regularity remained an independent predictor of self-termination [hazard ratio: 0.954 (0.928-0.980)]. Receiver operating characteristic (ROC) curve analysis of DF and RI intensities demonstrated increased predictability for self-termination in time with 95% CI above the 0.5 cut-off limit at about t = 8.6 s and t = 6.95 s, respectively. Consistent with the notion that fast organized sources maintain PVT/VF in humans, reduction of frequency and regularity correlates with early self-termination. Our findings might help generate ICD methods aiming to reduce inappropriate shock deliveries.

Optogenetic manipulation of cardiac electrical dynamics using sub-threshold illumination: dissecting the role of cardiac alternans in terminating rapid rhythms

Abstract Funding Acknowledgements Type of funding sources: None. Cardiac action potential (AP) shape and propagation are regulated by several key dynamic factors such as ions channel recovery and intracellular Ca2+-cycling. Experimental methods for manipulating AP electrical dynamics commonly use ion channel inhibitors that lack spatial and temporal specificity. In this work, we propose a novel approach based on optogenetics to manipulate cardiac electrical activity employing a light-modulated depolarizing current with intensities that are too low to elicit APs (sub-threshold illumination) but are sufficient to fine-tune AP electrical dynamics. We investigated the effects of sub-threshold illumination in isolated cardiomyocytes and whole hearts by using transgenic mice constitutively expressing a light-gated ion channel (channelrhodopsins-2, ChR2). We find that ChR2-mediated depolarizing current prolongs APs and reduces conduction velocity (CV) in a space-selective and reversible manner. Sub-threshold manipulation also affects the dynamics of cardiac electrical activity, increasing the magnitude of cardiac alternans. We use an optical system that uses real-time feedback control to generate re-entrant circuits with user-defined cycle lengths to explore the role that cardiac alternans plays in spontaneous termination of ventricular tachycardias (VTs). We find that VT stability significantly decreases during sub-threshold illumination primarily due to an increase in the amplitude of electrical oscillations, which implies that cardiac alternans may be beneficial in the context of self-termination of VT.

Evaluation of the Novel Automated Anti-Tachycardia Pacing Algorithm Successfully Terminating Sustained Monomorphic Ventricular Tachycardia in an Electrophysiology Study.

We report the usefulness of novel automated anti-tachycardia pacing (ATP) for ventricular tachycardia (VT) termination evaluated in an electrophysiology study. This intrinsic, automated ATP with an implanted cardiac resynchronization therapy-defibrillator successfully terminated the sustained VT, which had not been suppressed by repetitive burst pacing from the electrode catheter. The reproduction of programed pacing of the automated ATP by a right ventricular electrode catheter was effective in terminating VT, and this termination was absolute and reproducible. Further detailed assessment in an electrophysiology study could highlight the algorithm of the automated ATP and its possible benefit in terminating the reentrant VT.